DE602004028266D1 - Angiogene peptide und ihre verwendungen - Google Patents

Angiogene peptide und ihre verwendungen

Info

Publication number
DE602004028266D1
DE602004028266D1 DE602004028266T DE602004028266T DE602004028266D1 DE 602004028266 D1 DE602004028266 D1 DE 602004028266D1 DE 602004028266 T DE602004028266 T DE 602004028266T DE 602004028266 T DE602004028266 T DE 602004028266T DE 602004028266 D1 DE602004028266 D1 DE 602004028266D1
Authority
DE
Germany
Prior art keywords
angiogenic peptides
peptide
peptides
amino acid
angiogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004028266T
Other languages
English (en)
Inventor
Britta Hardy
Alexander Battler
Annat Raiter
Ran Kornowski
Chana Weiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of DE602004028266D1 publication Critical patent/DE602004028266D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
DE602004028266T 2003-10-29 2004-10-28 Angiogene peptide und ihre verwendungen Active DE602004028266D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51489503P 2003-10-29 2003-10-29
US55855804P 2004-04-02 2004-04-02
PCT/IL2004/000992 WO2005039616A1 (en) 2003-10-29 2004-10-28 Angiogenic peptides and uses thereof

Publications (1)

Publication Number Publication Date
DE602004028266D1 true DE602004028266D1 (de) 2010-09-02

Family

ID=34527062

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004028266T Active DE602004028266D1 (de) 2003-10-29 2004-10-28 Angiogene peptide und ihre verwendungen

Country Status (6)

Country Link
US (2) US7473682B2 (de)
EP (1) EP1677813B1 (de)
JP (1) JP2008500015A (de)
AT (1) ATE474589T1 (de)
DE (1) DE602004028266D1 (de)
WO (1) WO2005039616A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1677813B1 (de) * 2003-10-29 2010-07-21 Ramot at Tel Aviv University Ltd. Angiogene peptide und ihre verwendungen
WO2006138675A2 (en) 2005-06-15 2006-12-28 The Ohio State University Research Foundation Her-2 peptides
DE102005031755B9 (de) * 2005-07-01 2010-04-08 Technische Universität Dresden Salmonella spp. bindende Peptide, dafür kodierende Nukleinsäuren, deren Verwendungen und Verfahren und Kits zur Anreicherung, Immobilisierung und zum Nachweis von Salmonella spp.
CN101319008B (zh) * 2005-09-27 2010-12-01 南开大学 与肿瘤转移细胞特异性结合的多肽及其应用
US8227413B2 (en) * 2006-10-19 2012-07-24 Ramot At Tel-Aviv University Ltd. Compositions and methods for inducing angiogenesis
WO2010052715A2 (en) * 2008-11-07 2010-05-14 Ramot At Tel Aviv University Ltd. Devices and methods for local treatment of cardiovascular diseases
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
EP2385057A1 (de) * 2010-05-05 2011-11-09 Centre National de la Recherche Scientifique Peptidderivate zur Biofunktionalisierung von Siliciumsubstraten und deren Anwendungen
WO2012078671A2 (en) * 2010-12-06 2012-06-14 Massachusetts Institute Of Technology Tricalcium phosphate binding peptides and use thereof
DE102011003944A1 (de) 2011-02-10 2012-08-16 Oxprotect Gmbh Detektion und Entfernung von missgefalteten Proteinen/Peptiden
EP3864025A4 (de) 2018-10-12 2022-07-20 Theradaptive, Inc. Polypeptide mit einer beta-tricalciumphosphatbindenden sequenz und deren verwendungen

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638911B1 (en) * 1998-05-05 2003-10-28 Adherex Technologies Inc. Compounds and methods for modulating desmosomal cadherin-mediated functions
EP1136082A1 (de) * 2000-03-24 2001-09-26 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Lokalen Arzneistoffabgabe
CA2452445C (en) 2000-06-29 2011-02-15 North Shore-Long Island Jewish Health System Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
US20030113714A1 (en) * 2001-09-28 2003-06-19 Belcher Angela M. Biological control of nanoparticles
AU2002331890A1 (en) * 2001-09-20 2003-04-01 University Of Rochester Compositions and methods involved in bone growth
US20030166004A1 (en) 2001-11-01 2003-09-04 Jeno Gyuris Endothelial-cell binding peptides for diagnosis and therapy
US7323542B2 (en) * 2002-02-21 2008-01-29 University Of Virginia Patent Foundation Bone targeting peptides
US20030221931A1 (en) * 2002-02-28 2003-12-04 Steve Marsh Sliding device
EP1677813B1 (de) * 2003-10-29 2010-07-21 Ramot at Tel Aviv University Ltd. Angiogene peptide und ihre verwendungen
US7531505B2 (en) * 2006-01-11 2009-05-12 Affinergy, Inc. Compositions and methods for promoting attachment of cells of endothelial cell lineage to medical devices
US20080047370A1 (en) * 2006-08-07 2008-02-28 Vickery James H Jr Sampling apparatus for constituents in natural gas lines
US8227413B2 (en) * 2006-10-19 2012-07-24 Ramot At Tel-Aviv University Ltd. Compositions and methods for inducing angiogenesis

Also Published As

Publication number Publication date
EP1677813B1 (de) 2010-07-21
EP1677813A1 (de) 2006-07-12
ATE474589T1 (de) 2010-08-15
WO2005039616A1 (en) 2005-05-06
US20090163405A1 (en) 2009-06-25
JP2008500015A (ja) 2008-01-10
US20070082849A1 (en) 2007-04-12
US7473682B2 (en) 2009-01-06

Similar Documents

Publication Publication Date Title
ATE280826T1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
RS50966B (sr) Agonisti pyy i njihova upotreba
RS52815B (sr) Vezivna sredstva koja inhibiraju miostatin
MX2010002001A (es) Peptido cdca1 y agente farmaceutico que comprende elmismo.
ATE368053T1 (de) Antimikrobielle peptide
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
MX2010002018A (es) Peptido de cdh3 y agente medicinal que comprende al mismo.
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen
ATE495247T1 (de) Chromoprotein und fluoroproteine
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
CY1109946T1 (el) Τροποποιημενα πεπτιδια και η χρηση τους για τη θεραπεια αυτοανοσων νοσων
NZ591827A (en) Biologically active peptides comprising PTTKTYFPHF and their uses in the manufacture of a medicament for modulating immune reaction in a radiotherapy-induced immuno-compromised subject
DK1504036T3 (da) Toxinrelaterede fragmenter af antistoffer med antimikrobiel og antiviral aktivitet
ATE362769T1 (de) Lineare kationische peptide mit fungizider wirksamkeit
DE60236330D1 (de) Biologisch aktive Peptide
AR026068A1 (es) Peptidos modificados y peptidomimeticos para el uso en inmunoterapia.
EP1557466A4 (de) Tumorantigenprotein und dessen verwendung
GB0207644D0 (en) Peptides and their use
MXPA05004849A (es) Novedosas composiciones de multiples peptidos antigenicos relacionados con inhibina, que mejoran el desempeno de produccion avicola.
SE9700301D0 (sv) New compound
SG170757A1 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
ATE305478T1 (de) Topoisomerase-ii inhibitoren
DE60008749D1 (de) Therapeutische peptide aus untersequenzen von bpi
TW200611913A (en) Biologically active peptides (Ⅲ)
CY1115911T1 (el) Τροποποιημενα πολυπεπτιδια περιοχης kunitz και η χρηση τους στην μειωση της ισχαιμιας ή της εκκινησης μιας συστημικης φλεγμονωδους ανταποκρισης που σχετιζεται με μια χειρουργικη επεμβαση